IMFINZI® (durvalumab) Receives US Priority Review for Muscle-Invasive Bladder Cancer
AstraZeneca has announced that its supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review. This application aims to expand the treatment options for patients with muscle-invasive bladder…
Children’s Hospital LA Marks 100th Retinal Gene Therapy Procedure
Aaron Nagiel, MD, PhD, a leading pediatric retinal specialist at Children’s Hospital Los Angeles (CHLA), often hears stories from parents long after their child’s retinal gene therapy treatment. These heartfelt updates highlight significant improvements, such as a toddler seeing animals…
Alithea Genomics Unveils Full-Length DRUG-Seq for Enhanced Drug Discovery
Alithea Genomics, a leader in RNA sequencing and transcriptomics, has introduced its MERCURIUS™ Full-Length DRUG-seq library preparation technology. This groundbreaking innovation combines massive sample multiplexing, an extraction-free workflow, and full transcript coverage, creating a unique RNA-seq workflow. The technology is…
Innate Pharma and IFLI Announce Up to $7.9M Investment for IPH6501 Development in Follicular Lymphoma
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and the Institute for Follicular Lymphoma Innovation (IFLI) have entered into a strategic partnership to investigate the potential of IPH6501, Innate’s anti-CD20 ANKET® (Antibody-based NK cell Engager Therapeutics), in the treatment of…
Datopotamab Deruxtecan Shows Promise in EGFR-Mutated NSCLC
A pooled analysis of the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials demonstrated that datopotamab deruxtecan (Dato-DXd) achieved significant clinical responses in patients with previously treated advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). These findings, including progression-free…
Pfizer Highlights Leadership in Breast Cancer and Blood Disorders at ASH and SABCS
Pfizer Inc. (NYSE: PFE) is set to showcase significant advancements in its hematology and breast cancer portfolios at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December…
UGN-102 Shows Promising Long-Term Results in Phase 3 ENVISION Trial for LG-IR-NMIBC
UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing innovative treatments for urothelial and specialty cancers, has announced the presentation of the Phase 3 ENVISION trial’s efficacy and safety results at the Society of Urologic Oncology (SUO) annual…
MaaT Pharma Treats First U.S. Patient with MaaT013 for Acute GvHD at City of Hope
MaaT Pharma, a clinical-stage biotechnology company specializing in Microbiome Ecosystem Therapies™ (MET) to improve cancer patient survival, announced the first treatment in the United States of a patient with acute Graft-versus-Host Disease (aGvHD) under the FDA’s Single Patient Expanded Access…
MEDIPAL and JCR Pharmaceuticals Begin Phase I/II Trial of JR-446 for MPS IIIB in Japan
MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced today the initiation of the Phase I/II clinical trial for JR-446 in Japan, with the first participant dosed. JR-446 is a proprietary α-N-acetylglucosaminidase designed to…
XPRIZE Healthspan Offers USD$10 Million Bonus to Accelerate FSHD Breakthroughs
SOLVE FSHD, a venture philanthropy organization focused on accelerating new therapies for facioscapulohumeral muscular dystrophy (FSHD), is inviting innovators from around the globe to compete for the USD$10 million FSHD Bonus Prize. This prize is part of the XPRIZE Healthspan…
Cencora Unveils Accelerate Pharmacy Solutions to Boost Hospital and Health System Support
Cencora, a global healthcare leader, has introduced Accelerate Pharmacy Solutions, a comprehensive suite of services aimed at helping hospital and health system customers streamline operations and improve financial performance. This new portfolio consolidates Cencora’s pharmacy and supply chain solutions, providing…
VSee Health and AbundaBox Launch AbundaLife™ to Revolutionize Family Health Record Management
VSee Health, Inc. (Nasdaq: VSEE), a leader in telehealth solutions known for its scalable technology and clinical expertise, has partnered with AbundaBox to launch AbundaLife™, an innovative health record management platform. AbundaLife addresses the challenge of fragmented medical records by…